Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China

Authors: Qian Zhang, Yi-Jun Liu, Shang-Ying Hu, Fang-Hui Zhao

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Human papillomavirus (HPV) 16 and 18 are the two most common HPV oncogenic types that can be prevented by vaccination. This study aimed at assessing the cost-effectiveness of 3 doses of the bivalent HPV vaccine in rural and urban settings in China.

Methods

A Markov model was adapted to reflect the lifetime of a modelled 100,000 12-year-old girls cohort in rural and urban settings in China. Input parameters were obtained from published literature, official reports and a two-round expert review panel. Clinical and economic outcomes of vaccination at age 12 with screening was compared to screening only. In the base case analysis, a 3 % discount rate, the vaccine cost of 247 CNY (US$ 39, PAHO vaccine cost in 2013), two rounds of screening in a life time and 70 % coverage for both screening and vaccination were used. One-way, two-way and probabilistic sensitivity analyses were performed. We used different thresholds of cost-effectiveness to reflect the diversity of economic development in China.

Results

Vaccination in addition to screening could prevent 60 % more cervical cancer cases and deaths than screening only. The incremental cost effectiveness ratio varied largely when changing cost of vaccination and discount in one way analysis. Vaccination was very cost-effective when the vaccine cost ranged 87-630 CNY (US$ 13.8-100) in rural and 87-750 CNY (US$ 13.8–119) in urban; and remained cost-effective when the vaccine cost ranged 630–1,700 CNY (US$ 100–270) in rural and 750–1,900 CNY (US$ 119–302) in urban in two way analysis. Probabilistic sensitivity analyses showed that model results were robust.

Conclusions

In both rural and urban, the vaccination cost and discounting are important factors determining the cost-effectiveness of HPV vaccination; policy makers in China should take these into account when making a decision on the introduction of HPV vaccine. In areas with a high burden of cervical cancer and limited screening activities, HPV vaccination should be prioritized. However, the vaccine cost needs to be reduced in order to make it very cost-effective and affordable as well, in particular in poverty areas with high disease burden.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr. Accessed 26 Dec 2014.
2.
Yang L, Parkin DM, Li L, Chen Y. Time trends in cancer mortality in China: 1987-1999. Int J Cancer. 2003;106:771–83.CrossRefPubMed
3.
Chen WQ, Zheng RS, Zeng HM, Zou XN, Zhang SW, He J. [Report of cancer incidence and mortality in china, 2011] [in Chinese]. China Cancer. 2015;24:1–10.CrossRef
4.
Zur Hausen H. Papillomaviruses in human cancer. Appl Pathol. 1987;5:19–24.PubMed
5.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.CrossRefPubMed
6.
Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control. 2009;20:1705–13.CrossRefPubMed
7.
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14.CrossRefPubMed
8.
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55.CrossRefPubMed
9.
Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer. 2014;135:2612–22.CrossRefPubMedPubMedCentral
10.
11.
12.
Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics. 2011;29:371–86.CrossRefPubMed
13.
14.
Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making. 2006;26:434–46.CrossRefPubMed
15.
Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health. 2011;56:153–62.CrossRefPubMed
16.
Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, et al. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med. 2011. doi:10.​1186/​1741-7015-9-54.
17.
Goldie SJ, O’Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26:4080–93.CrossRefPubMed
18.
Jit M, Levin C, Brisson M, Levin A, Resch S, Berkhof J, et al. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysis. BMC Med. 2013. doi:10.​1186/​1741-7015-11-23.PubMedPubMedCentral
19.
Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine. 2011;29:2487–94.CrossRefPubMed
20.
Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, et al. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Vaccine. 2015;33:2830–41.CrossRefPubMed
21.
Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine. 2008;26 Suppl 5:F16–28.CrossRefPubMed
22.
Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer. 2010;20:385–92.CrossRefPubMed
23.
24.
Jeffrey DS. Macroeconomics and health. Health: investing in health for economic development. 2001.
25.
26.
27.
28.
29.
Shi JF, Chen JF, Canfell K, Feng XX, Ma JF, Zhang YZ, et al. Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Serv Res. 2012. doi:10.​1186/​1472-6963-12-123.
30.
Zhao FH, Chen JF, Gao XH, Gao LM, Liu QG, Liu ZH, et al. [Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment] [in Chinsese]. Zhonghua Zhong Liu Za Zhi. 2012;34:632–6.PubMed
31.
Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer. 2011;11:239.CrossRefPubMedPubMedCentral
32.
Liu YJ, Zhang Q, Hu SY, Zhao FH. Costs of detection and treatment of cervical cancer, cervical intraepithelial neoplasias in China. Asia-Oceania Research Organisation in Genital Infection and Neoplasia (AOGIN) 2014, Beijing, China.
33.
34.
PAHO (Pan American Health Organization). Expanded Program of Immunization Vaccine Prices for Year 2013- Amendment III.
35.
36.
37.
Yu WZ, Yu JJ, Cui G, Jin SG, Wag J, Tao Z. [Study on the reasonable cost of national immunization program in some regions of china] [in Chinese]. Chinese JVaccines Immun. 2006;4:280–4.
38.
Suárez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008;26 Suppl 5:F29–45.CrossRefPubMed
39.
Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96(8):604–15.CrossRefPubMed
40.
Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778–92.CrossRefPubMed
41.
Trogdon JG, Ekwueme DU, Subramanian S, Crouse W. Economies of scale in federally-funded state-organized public health programs: results from the National Breast and Cervical Cancer Early Detection Programs. Health Care Manag Sci. 2013;17(4):321–30.CrossRefPubMed
42.
Vale DB, Morais SS, Pimenta AL, Zeferino LC. [Assessment of the cervical cancer screening in the Family Health Strategy in Amparo, Sao Paulo State, Brazil. Cad Saude Publica. 2010;26:383–90.CrossRefPubMed
43.
Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11:1160–71.CrossRefPubMed
44.
Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995–3002.CrossRefPubMed
45.
Van de Velde N. Brisson M, Boily MC, Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165:762–75.CrossRefPubMed
46.
47.
Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727–35.PubMed
48.
Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2006;95 Suppl 1:S43–103.CrossRefPubMed
49.
Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99.CrossRefPubMed
50.
Cagle AJ, Hu SY, Sellors JW, Bao YP, Lim JM, Li SM, et al. Use of an expanded gold standard to estimate the accuracy of colposcopy and visual inspection with acetic acid. Int J Cancer. 2010;126(1):156–61.CrossRefPubMed
51.
Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9(10):929–36.CrossRefPubMed
52.
Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.CrossRefPubMed
53.
Xu H, Zhao FH, Gao XH, Hu SY, Chen JF, Liu ZH, et al. [Cost-effectiveness analysis on the once in a life time cervical cancer screening program for women living in rural and urban areas of China] [in Chinese]. Zhonghua liu xing bing xue za zhi. 2013;34:399–403.PubMed
54.
Li Q, Liu ZH, Liu ST, Li XL, Huang ME, Ye ML, et al. [Opportunistic Screening for cervical cancer in City Hospital] [in Chinese]. Chinese Cancer. 2008;17:176–8.
55.
Cancer, I.A.f.R.o. IARC handbooks of cancer prevention Vol. 10. Cervix cancer screening. Lyon: IARC Press; 2005.
56.
World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. 14th ed. Geneva: World Health Organization; 2008.
57.
Women’s health in rural China. Lancet. 2009;374:358.
58.
59.
Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer. 2012;130:641–52.CrossRefPubMed
60.
Ogembo JG, Manga S, Nulah K, Foglabenchi LH, Perlman S, Wamai RG, et al. Achieving high uptake of human papillomavirus vaccine in Cameroon: lessons learned in overcoming challenges. Vaccine. 2014;32:4399–403.CrossRefPubMed
61.
Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine. 2015;33:1608–13.CrossRefPubMed
62.
Goldie SJ, O’Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters. 2008;16(32):86–96.CrossRefPubMed
63.
Levin A, Wang SA, Levin C, Tsu V, Hutubessy R. Costs of introducing and delivering HPV vaccines in Low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. PLoS One. 2014. doi:10.​1371/​journal.​pone.​0101114.
64.
Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283(11):1460–8.CrossRefPubMed
65.
Kim JJ, Sharma M, O’Shea M, Sweet S, Diaz M, Sancho-Garnier H, et al. Model-based impact and cost-effectiveness of cervical cancer preventionin the Extended Middle East and North Africa (EMENA). Vaccine. 2013;31 Suppl 6:G65–77.CrossRefPubMed
66.
Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014. doi:10.​1016/​S2214-109X(14)70237-2.
67.
Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31(37):3786–804.CrossRefPubMed
68.
69.
Kim JJ, Campos NG, O’Shea M, Diaz M, Mutyaba I. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-saharan Africa. Vaccine. 2013;31 Suppl 5:F60–72.CrossRefPubMed
70.
71.
72.
73.
Zhang SK, Pan XF, Wang SM, Yang CX, Gao XH, Wang ZZ, et al. Perceptions and acceptability of HPV vaccination among parents of young adolescents: A multicenter national survey in China. Vaccine. 2013;31:3244–9.CrossRefPubMed
74.
Zhao FH, Tiggelaar SM, Hu SY, Zhao N, Hong Y, Niyazi M, et al. A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials, and medical personnel in China. Asian Pac J Cancer Prev. 2012;13:2369–78.CrossRefPubMed
75.
Wang SM, Zhang SK, Pan XF, Ren ZF, Yang CX, Wang ZZ, et al. Human papillomavirus vaccine awareness, acceptability, and decision-making factors among Chinese college students. Asian Pac J Cancer Prev. 2014;15:3239–45.CrossRefPubMed
76.
77.
Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24 Suppl 3:S3/106–13.
78.
Gaudet M, Hamm J, Aquino-Parsons C. Incidence of ano-genital and head and neck malignancies in women with a previous diagnosis of cervical intraepithelial neoplasia. Gynecol Oncol. 2014;134:523–6.CrossRefPubMed
79.
80.
Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancerand pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One. 2014. doi:10.​1371/​journal.​pone.​0088323.
Metadata
Title
Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China
Authors
Qian Zhang
Yi-Jun Liu
Shang-Ying Hu
Fang-Hui Zhao
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2893-x

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy

Research article

Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011

Research article

Computerized tomography angiography in preoperative assessment of intravenous leiomyomatosis extending to inferior vena cava and heart

Research article

Prevalence and correlates of healthy lifestyle behaviors among early cancer survivors

Research article

Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties

Research article

Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits